Madrigal Pharmaceuticals delivered eight Rezdiffra (resmetirom) poster presentations at EASL 2026 today. Key data: secondary analysis of MAESTRO-NASH and MAESTRO-NAFLD-1 documented Rezdiffra-driven improvements in cardiovascular lipid risk markers (Lp(a), LDL-C, ApoB); a two-year analysis in patients with compensated MASH cirrhosis (F4c) showed meaningful improvement in ANTICIPATE-NASH risk scores, a validated marker for clinically significant portal hypertension. Real-world effectiveness analyses and noninvasive biomarker plus machine-learning models for predicting MASH and fibrosis improvement rounded out the presentation slate. Rezdiffra (resmetirom) — a thyroid hormone receptor β agonist small molecule, not a peptide — was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The compensated MASH cirrhosis (F4c) data extend the case toward an indication where the GLP-1/glucagon peptide programs (pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) are also competing.
Sagimet Biosciences presented two posters at EASL 2026 today on the combination of its denifanstat (FASN inhibitor small molecule) with Madrigal's Rezdiffra (resmetirom, thyroid hormone receptor β agonist) for MASH. The combination work tests whether layered MASH therapies producing complementary mechanism-of-action effects can outperform either monotherapy. Denifanstat inhibits fatty acid synthase — the enzyme producing the majority of newly synthesized fatty acids in the liver — reducing hepatic lipogenesis upstream of the inflammation and fibrosis cascade that resmetirom addresses through downstream thyroid-hormone-receptor mechanisms. The combination represents the broader trend of MASH-as-multi-mechanism-battleground that defines EASL 2026: GLP-1/glucagon peptides (pemvidutide, DA-1726, survodutide), RNAi (ARO-INHBE), thyroid hormone agonism (Rezdiffra), FASN inhibition (denifanstat), and galectin-3 inhibition (belapectin) all running parallel programs.
Madrigal Pharmaceuticals announced May 20 that multiple abstracts from its Rezdiffra (resmetirom) development and real-world evidence programs will be presented at EASL 2026 in Barcelona. Headline analyses include cardiovascular risk markers — secondary analysis of Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 examining improvements in Lp(a), LDL-C, and ApoB — and portal hypertension risk improvement in compensated MASH cirrhosis (F4c) measured by ANTICIPATE-NASH risk scores. Real-world evidence and noninvasive biomarker analyses round out the slate. Rezdiffra (a thyroid hormone receptor β agonist, not a peptide) was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The EASL data extend the case toward compensated MASH cirrhosis and cardiovascular outcomes — a competitive context for the GLP-1/glucagon peptide programs (semaglutide ESSENCE, pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) running on parallel tracks.